Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI
|
|
- Melissa Cecilia Cole
- 5 years ago
- Views:
Transcription
1 Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI 8 Alan Yean Yip Fong and Hwei Sung Ling 8.1 Introduction Platelet inhibition remains the core pharmacotherapy component in patients undergoing emergency or primary percutaneous coronary interventions (PCI). This can be achieved using a number of intravenous and oral preparations. Intravenous (iv) antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the only available intravenous P 2 Y 12 inhibitor, cangrelor. Available oral agents include aspirin and various P 2 Y 12 inhibitors or their analogues. These are usually used in combination with the intention to maintain dual antiplatelet therapy (DAPT) for a period of time (generally up to 12 months) after the index PCI procedure. Understanding and appropriate use of antiplatelet agents are vital in optimizing clinical outcomes of patients with acute coronary syndromes, particularly in the emergency setting where the patient may be naïve to all pharmacological agents. In this review, an overview on antiplatelet therapy for patient needing emergency PCI is described, including evidence from important clinical trials and suggested antiplatelet therapy regimens by published clinical practice guidelines. 8.2 Aspirin Aspirin (acetylsalicylic acid) ( 75 mg daily) permanently inhibits plateletdependent cyclooxygenase 1 (COX-1) enzyme and consequently preventing synthesis of and thromboxane A 2 (TXA 2 ), which is a powerful promoter of platelet aggregation [1]. At higher doses, aspirin inhibits COX-2 which offers analgesic and A. Y. Y. Fong (*) Sarawak Heart Centre, Kota Samarahan, Malaysia alanfong@crc.gov.my H. S. Ling Sarawak General Hospital, Kuching, Malaysia The Author(s) 2018 T. J. Watson et al. (eds.), Primary Angioplasty, 99
2 100 A. Y. Y. Fong and H. S. Ling antipyretic effects by blocking production of prostaglandin. Aspirin in a broad range of patients has been shown to offer clinically important benefits on protection from coronary artery disease (CAD). This predominantly appears related to antiplatelet effects, although the drug may also play a role in reducing atherosclerosis by blocking COX-dependent vasoconstrictors and prevent oxidation of low density lipoprotein. Importantly, aspirin has become a central component of the antiplatelet regimen both for patients with established CAD and those undergoing PCI procedures Evidence of Aspirin in Myocardial Infarction and PCI Major studies indicating a central role for aspirin in patients with acute MI and undergoing emergency revascularization include: International Study of Infarct Survival (ISIS-2) [2] This study was performed in the thrombolysis era but demonstrated a headline 23% reduction of mortality rate among patients with MI with a near to 50% reduction of nonfatal reinfarction or stroke. Meta-analysis of aspirin usage for prevention of stroke, myocardial infarction, and death among high-risk patients [3] This study from the Antithrombotic Trialists Collaboration showed a 53% reduction of death and vascular events in those underwent coronary angioplasty. Aspirin in prevention of restenosis after PCI [4] This study showed that in addition to protection from stent thrombosis, aspirin offered a significant reduction of stent restenosis rate after PCI Aspirin Dosing Consensus with regard to dosing of aspirin before and after PCI (including primary PCI) has been established and recommended as follows [5]: Loading (prior to PCI) Tablet mg stat dose if not on chronic aspirin therapy, at least 2 h before PCI Tablet mg stat dose if already on chronic aspirin therapy Maintenance therapy (post PCI) Tablet mg OD to continue indefinitely 8.3 P 2 Y 12 Inhibitors The P 2 Y 12 receptor plays a key role in the platelet activation process. Adenosine diphosphate (ADP) interacts with the platelet P 2 Y 12 receptor stimulating activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. In turn, activation of the GP2b3a
3 8 Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI 101 receptor results in enhanced platelet degranulation and thromboxane production, driving platelet aggregation [6]. Various P 2 Y 12 inhibitors are available. Clopidogrel and prasugrel are thienopyridine prodrugs that must undergo cytochrome P450-mediated conversion to the active metabolite which then covalently bond to the P 2 Y 12 receptor, thus inhibiting platelet activation. In contrast, ticagrelor and cangrelor are direct-acting platelet inhibitors which do not need activation. These agents are thus more potent and have more rapid onset of action Evidence for P 2 Y 12 Inhibitor in MI and PCI CURE (PCI-CURE) [7] This trial showed a significant reduction of cardiovascular death and myocardial infarction post PCI using clopidogrel. TRITON-TIMI 38 [8] This trial showed a significant reduction of cardiovascular death, nonfatal myocardial infarction, and stroke using prasugrel among patients with high-risk ACS undergoing PCI. Of note, patients with prior stroke, transient ischemic attack (TIA), age > 75, and weight < 60 kg had no net benefit. PLATO [9] This trial showed a reduction of composite death from vascular causes, MI, and stroke with use of ticagrelor. Of note, patients with prior stroke, TIA which led to net harm, age > 75, and weight < 60 kg had no net benefit P 2 Y 12 Inhibitor Dosing Clopidogrel Loading (prior to PCI) Tablet mg stat dose Maintenance therapy Tablet mg OD Prasugrel Loading (prior to PCI) Tablet 60 mg stat dose Maintenance therapy Tablet 10 mg OD Tablet 5 mg OD (if body weight < 60 kg) Ticagrelor Loading (prior to PCI). Tablet 180 mg stat dose Maintenance therapy Tablet 90 mg BD
4 102 A. Y. Y. Fong and H. S. Ling 8.4 Glycoprotein IIb/IIIa Inhibitors GPIIb/IIIa inhibitors directly target the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. This receptor is the most abundant integrin found on the surface of platelets and is composed of two separate subunits, α IIb (GPIIb) and β 3 (GPIIIa). GPIIb/ IIIa inhibitors prevent binding of primarily fibrinogen, but various other ligands also, hence, inhibit the aggregation of platelets [10]. Various agents are available: Abciximab is a monoclonal antibody. Eptifibatide is a synthetic cyclic heptapeptide. Tirofiban is a nonpeptidal antagonist to glycoprotein IIb/IIIa receptor Evidence for GPIIb/IIIa Inhibitors in MI and PCI Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndrome [10] Review of multiple trials showed statistically significant benefit in GPIIb/IIIa treatment groups in terms of composite outcome of death, subsequent MI, and revascularization. Evaluation of 7e3 for Prevention of Ischemic Complication (EPIC) [11] Usage of abciximab during coronary angioplasty after presentation with highrisk unstable angina showed significant reduction in composite death, nonfatal MI, repeat coronary artery bypass grafting (CABG), repeat PCI for recurrent ischemia, or requirement for a coronary stent after balloon angioplasty. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) [12] Usage of eptifibatide in patient with ST changes and MI (but not persistent ST elevation) together with aspirin and intravenous heparin, via infusion for up to 96 h, significantly reduces composite of death and nonfatal myocardial infarction within 30 days from index event. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) [13] Usage of tirofiban with heparin infusion in patient with acute myocardial infarction for up to 72 h showed significant decrease of 7 days to 30 days composite death, recurrent myocardial infarction Dosing Abciximab Bolus of 0.25 mg/kg intravenous Infusion at μg/kg/min (maximum 10ug/min) for 12 h
5 8 Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI 103 Eptifibatide Double bolus of 180 μg/kg intravenous (given at 10-min interval) Infusion 2.0 μg/kg/min for up to 18 h Tirofiban Bolus of 25 μg/kg over 3 min Infusion at 0.15 μg/kg/min for up to 18 h DAPT and glycoprotein IIb/IIIa inhibitor in emergency PCI 8.5 Recommended Treatment Algorithms from Consensus Guidelines [14, 15] 1. A potent, faster onset and superior clinical efficacy P 2 Y 12 inhibitor (prasugrel or ticagrelor) is recommended ideally prior to (or at least at the time of) PCI. 2. Ticagrelor is recommended as P 2 Y 12 inhibitor of choice on top of aspirin in patients with ACS. 3. Ticagrelor should not be used in patient with previous intracranial hemorrhage or ongoing bleeds or on oral anticoagulants. 4. Prasugrel should not be used in patient with previous intracranial hemorrhage, previous ischemic stroke or transient ischemic attack, or ongoing bleeds or on oral anticoagulants. Prasugrel is generally not recommended in patient >75 years old or weighing <60 kg. 5. In cases prasugrel is used for patient >75 years old or weighing <60 kg, a dose of 5 mg OD should be used. 6. When none of the ticagrelor or prasugrel can be used, clopidogrel can be the choice of P 2 Y 12 inhibitor. 7. Switching from clopidogrel to either ticagrelor or prasugrel in acute setting need not consider prior clopidogrel timing and dosing (Fig. 8.1). Time of use DAPT duration strategies assessed PRECISE-DAPT score 18 At the time of coronary stenting Short DAPT (3-6 months) vs. Standard/long DAPT (12-24 months) DAPT score 15 After 12 months of uneventful DAPT Standard DAPT (12 months) vs. Long DAPT (30 months) Score calculation 2 Score range Decision making cut-of suggested HB Age WBC to < <65 Age Cigarette smoking Diabetes mellitus CrCI MI at presentation Prior PCI or prior MI Prior Paclitaxel-eluting stent Yes No Bleeding Stent diameter <3 mm Score CHF or LVEF <30% points Vein graft stent 0 to 100 points Score 25 Short DAPT Score <25 Standard/long DAPT 2 to 10 points Score 2 Long DAPT Score <2 Standard DAPT 2 pt 1 pt 0 pt +2 pt +2 pt Calculator Fig. 8.1 Switching of P 2 Y 12 inhibitor product in acute setting [13]
6 104 A. Y. Y. Fong and H. S. Ling 8. Switching in between ticagrelor and prasugrel or from either one to clopidogrel in acute setting requires 24-h lapse since the last dose (Fig. 8.1). 9. Bleeding risk can be assessed using risk model, e.g., PRECISE-DAPT and DAPT score. Bleeding risk decides duration of DAPT (Fig. 8.2). 10. Suggested duration of DAPT (Fig. 8.3): (a) Acute coronary syndrome receiving PCI At least 12 months of DAPT (aspirin and a P 2 Y 12 inhibitor) is recommended. Six months of DAPT should be considered if there is high bleeding risk; with emerging data for abbreviated DAPT with certain stents, even earlier cessation may be possible. Extension of DAPT >12 months may be considered if no bleeding complication during initial treatment. Percutaneous Coronary Intervention Treatment indication Stable Coronary Artery Disease Acute Coronary Syndrome Device used DES/BMS or DCB BRS DES/BMS or DCB High Bleeding Risk High Bleeding Risk Time I mo. 3 mo. 6 mo. 12 mo. 30 mo. No A C 6 mo. DAPT Class I A A C Continue DAPT Class IIb A Yes No Yes A C 1 mo. DAPT Class IIb C 3 mo. DAPT Class IIa B A P A T A P A T A C OR A T OR 2 A C 12 mo. DAPT Class IIa C OR 3 A C 12 mo. DAPT Class II A A T OR 4 4 A P A C Continue DAPT >12 mo. in pts with prior MI Class IIa B 6 mo. DAPT Class IIa B A = Aspirin C = Clopidogrel P = Prasugrel T = Ticagrelor Fig. 8.2 Bleeding risk assessment before deciding duration of dual antiplatelet therapy [14]
7 8 Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI 105 CLOPIDOGREL Prasugrel LD (60 mg) irrespective of prior Clopidogrel timing and dosing Clopidogrel LD (600 mg) 24h after last Prasugrel dose ACUTE SETTING ALWAYS RELOAD Ticagrelor LD (180 mg) irrespective of prior Clopidogrel timing and dosing Clopidogrel LD (600 mg) 24h after last Ticagrelor dose PRASUGREL Ticagrelor LD (180 mg) 24h after last Prasugrel dose TICAGRELOR Prasugrel LD (60 mg) 24h after last Ticagrelor dose Fig. 8.3 Recommended duration of DAPT in patient undergoing PCI [14] (b) Benefits and risks of extended DAPT (18 36 months) Absolute decrease in risk of instent thrombosis, myocardial infarction, and major adverse cardiac events by 1 2%. Absolute increase in bleeding complications by 1%. More benefits are seen in patient with ACS rather stable IHD. 11. Types of stent and its duration: (a) Shorter duration (3 6 months) may be reasonable in patients treated with newer-generation stents as compared to first generation. Emerging data may permit even shorter duration; trials are awaited. 12. DAPT dose in chronic kidney disease: (a) Stages 1 3 EGFR >30 ml/min/1.73 m 2 Aspirin: Loading at mg orally, followed by maintenance 75 mg 100 mg/day Clopidogrel: Loading at mg orally, followed by 75 mg/day Ticagrelor: Loading at 180 mg orally, followed by 90 mg BD/day Prasugrel: Loading at 60 mg orally, followed by 10 mg/day (b) Stage 4 EGFR ml/min/1.73 m 2 No dose adjustment (c) Stage 5 EGFR <15 ml/min/1.73 m 2 Aspirin: No dose adjustment Clopidogrel: No information available Ticagrelor and prasugrel: NOT recommended
8 106 A. Y. Y. Fong and H. S. Ling 13. Glycoprotein IIb/IIIa inhibitor usage in prehospital or upstream settings has not shown extra benefits on efficacy of treatment. 14. Selective downstream usage of GPIIb/IIIa inhibitors reduces cost of treatment and bleeding risk [15]. 15. Usage of glycoprotein IIb/IIIa inhibitor during coronary catheterization as a bailout therapy can be considered. This includes large thrombus, slow or no reflow, or other findings of thrombotic complications during coronary angiogram [16]. 16. Special patient subgroup. In patients on oral anticoagulation who present with STEMI and are undergoing emergency PCI, these patients should: (a) Loading of aspirin and clopidogrel (the P 2 Y 12 inhibitor of choice, 600 mg loading dose) should be done. (b) Also receive additional parenteral anticoagulation. (c) Chronic oral anticoagulation therapy should not be stopped during admission. (d) Gastric protection with a proton pump inhibitor is recommended. (e) Triple therapy (oral anticoagulation, aspirin, and clopidogrel) should be considered for 6 months after STEMI. (f) Oral anticoagulation plus aspirin or clopidogrel should be considered for an additional 6 months; after which, it is then indicated to maintain oral anticoagulation. (g) For patients with atrial fibrillation as the indication for anticoagulation, rivaroxaban in combination with clopidogrel and without aspirin may be a reasonable choice. (h) The use of ticagrelor or prasugrel is not recommended as part of a triple therapy regimen with aspirin and oral anticoagulation. 8.6 Summary DAPT is an important periprocedural pharmacotherapy in patient receiving PCI. DAPT, aspirin, and a P 2 Y 12 inhibitor are to be loaded orally as soon as diagnosis of ACS was made. Choice of P 2 Y 12 inhibitor includes prasugrel, ticagrelor, and clopidogrel. Duration of DAPT treatment after emergency PCI depends on bleeding risk assessment and types of stents used. Extra attention in cases with bioresorbable vascular scaffold, which requires at least 12 months of DAPT regardless of bleeding risk. Glycoprotein IIb/IIIa inhibitor usage depends on treating physician justification as no conclusive evidence of its routine use in emergency PCI.
9 8 Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI 107 References 1. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004;25(2): Randomised trial of intravenous streptokinase, oral aspirin, both, or neither. among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2. (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607): Antithrombotic Trialists Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329): Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318(26) 5. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al ACCF/AHA/ SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23) 6. Wallentin L. P 2 Y 12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16): Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patientsundergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358: Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, RITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON- TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373: Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L, inhibition PLAT, Investigators p O. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. Technology appraisal guidance [TA47]. Published date: 05 September 2002; Last updated: 01 March The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330: Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101: PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338: Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol [internet]. 2016;68(10):
10 108 A. Y. Y. Fong and H. S. Ling 15. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;70(12): doi/ /eurheartj/ehx393/ /2017-esc-guidelines-for-the-management-of-acute 16. De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol. 2011;107(2): amjcard Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License ( which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this chapter are included in the chapter s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Learning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAntiplatelet therapy is the mainstay of pharmacological
Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationCOME ORIENTARSI TRA I NUOVI. Maria Rosa Conte H. Mauriziano Torino
COME ORIENTARSI TRA I NUOVI ANTIPIASTRINIC I Maria Rosa Conte H. Mauriziano Torino Sulle sponde del Ticino- Novara 10 maggio 2013 NEW ORAL ANTIPLATET AGENT PRASUGREL TICAGRELOR (Cangrelor) Death/ MI/
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationAcute Coronary Syndromes Compendium
Acute Coronary Syndromes Compendium Circulation Research Compendium on Acute Coronary Syndromes Acute Coronary Syndromes: Pathology, Diagnosis, Genetics, Prevention, and Treatment Mechanisms of Plaque
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationThe following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online.
Presentation 1 The following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational grant from Daiichi Sankyo
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationSheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationUpdate on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
More informationHigh-sensitive troponin. Introduction. Platelet aggregation inhibition at admission
Neth Heart J (2017) 25:181 185 DOI 10.1007/s12471-016-0939-y GUIDELINES 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More information2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationACUTE CORONARY SYNDROME
A supplement to MONTHLY PRESCRIBING REFERENCE April 2014 Issue #18 Intervention & Prevention: Keeping Current with ACUTE CORONARY SYNDROME JOURNAL CLUB Pretreatment with prasugrel in non-st-segment elevation
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationEuropean Heart Journal 2015 doi: /eurheartj/ehv320
European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationA patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for
More informationINNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.
INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies. José G. Díez, MD, FACC, FSCAI Associate Professor of Medicine, Baylor College of Medicine Hall Garcia
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationNewer Antiplatelets. Asha Moorthy, Jain T Kallarakkal, James Kumar P INTRODUCTION
ewer Antiplatelets Asha Moorthy, Jain T Kallarakkal, James Kumar P ITRODUCTIO Many therapeutic drugs have been identified that possess clinically important antiplatelet activity. Platelet inhibition can
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationANTIPLATELET REGIMENS:
ANTIPLATELET REGIMENS: How Long, How Many? John Carter Hemphill, M.D., F.A.C.C. Chattanooga Heart Institute February 10, 2018 I have no financial disclosures. DISCLOSURES: OBJECTIVES Understand current
More informationTHE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION
: 616.127-005.8 -..,.. -...,, ( ), 2011, 581 182. 195 592 ( ) 385 590 -. 4,3 % 8,8 % ( ). 2011 62 329,, 24 931 (40 %) -. : - - ; ; 70 % ST ( ST); ST - 24. : ST,. THE CURRENT SITUATION AND FUTURE OF THE
More informationDual Antiplatelet Therapy: Time for a Paradigm Shift?
Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationRobert Storey. Sheffield, United Kingdom
Antiplatelet in ACS Moving beyond clopidogrel Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary Consultant Cardiologist,
More informationConference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine
Conference Papers in Medicine, Article ID 719, pages http://dx.doi.org/1.1155/13/719 Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationSelective use of platelet glycoprotein IIb/IIIa inhibition
20 years clinical use of GP IIb/IIIa receptor antagonists: What have we learned and where to go? EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2014 Selective use of platelet glycoprotein
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More information